8VGV image
Deposition Date 2023-12-29
Release Date 2024-10-02
Last Version Date 2024-11-13
Entry Detail
PDB ID:
8VGV
Title:
DH270.6 Fab bound to the HIV-1 CH848 DE3 SOSIP
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.60 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:CH848 DE3 SOSIP gp120
Gene (Uniprot):env
Chain IDs:A, E, I
Chain Length:462
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:CH848 DE3 SOSIP gp41
Gene (Uniprot):env
Chain IDs:B, F, J
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:DH270.6 Antibody Fab Heavy Chain
Chain IDs:C, G, K
Chain Length:126
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:DH270.6 Antibody Fab Light Chain
Chain IDs:D, H, L
Chain Length:108
Number of Molecules:3
Biological Source:Homo sapiens
Primary Citation
Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.
Nat Commun 15 9503 9503 (2024)
PMID: 39489734 DOI: 10.1038/s41467-024-53120-9

Abstact

Vaccine development targeting rapidly evolving pathogens such as HIV-1 requires induction of broadly neutralizing antibodies (bnAbs) with conserved paratopes and mutations, and in some cases, the same Ig-heavy chains. The current trial-and-error search for immunogen modifications that improve selection for specific bnAb mutations is imprecise. Here, to precisely engineer bnAb boosting immunogens, we use molecular dynamics simulations to examine encounter states that form when antibodies collide with the HIV-1 Envelope (Env). By mapping how bnAbs use encounter states to find their bound states, we identify Env mutations predicted to select for specific antibody mutations in two HIV-1 bnAb B cell lineages. The Env mutations encode antibody affinity gains and select for desired antibody mutations in vivo. These results demonstrate proof-of-concept that Env immunogens can be designed to directly select for specific antibody mutations at residue-level precision by vaccination, thus demonstrating the feasibility of sequential bnAb-inducing HIV-1 vaccine design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures